{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:13:38Z","timestamp":1789409618690,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.critrevonc.2025.104719","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:03:17Z","timestamp":1744149797000},"page":"104719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Current landscape of hypoxia in thyroid cancer pathogenesis and treatment"],"prefix":"10.1016","volume":"211","author":[{"given":"Jianhong","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.critrevonc.2025.104719_bib1","doi-asserted-by":"crossref","first-page":"16116","DOI":"10.1074\/jbc.M115.643668","article-title":"Transient receptor potential canonical 1 (TRPC1) Channels as regulators of sphingolipid and vegf receptor expression: implications for thyroid cancer cell migration and proliferation","volume":"290","author":"Asghar","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104719_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib3","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.3390\/cimb46060323","article-title":"Unravelling the mysteries of the sonic hedgehog pathway in cancer stem cells: activity, crosstalk and regulation","volume":"46","author":"Berrino","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104719_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040557","article-title":"Hypoxia-activated theragnostic prodrugs (HATPs): current state and future perspectives","volume":"16","author":"Bhuniya","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib5","article-title":"Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses","volume":"14","author":"Cao","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104719_bib6","first-page":"2049","article-title":"Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer","volume":"35","author":"Cha","year":"2015","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113159","article-title":"Hypoxia promotes thyroid cancer progression through HIF1\u03b1\/FGF11 feedback loop","volume":"416","author":"Chen","year":"2022","journal-title":"Exp. Cell Res"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104719_bib8","doi-asserted-by":"crossref","first-page":"21546","DOI":"10.1021\/acsami.4c00793","article-title":"Oxygen-independent radiodynamic therapy: radiation-boosted chemodynamics for reprogramming the tumor immune environment and enhancing antitumor immune response","volume":"16","author":"Chen","year":"2024","journal-title":"ACS Appl Mater. Interfaces"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104719_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","article-title":"Advances in hypoxia-inducible factor biology","volume":"27","author":"Choudhry","year":"2018","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib10","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.3892\/etm.2016.3826","article-title":"Silencing of hypoxia-inducible factor-1\u03b1 promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2","volume":"12","author":"Ding","year":"2016","journal-title":"Exp. Ther. Med"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104719_bib11","first-page":"6570","article-title":"MiR-548c-3p suppressed the progression of papillary thyroid carcinoma via inhibition of the HIF1\u03b1-mediated VEGF signaling pathway","volume":"23","author":"Du","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104719_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14489","article-title":"A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response","volume":"30","author":"Duan","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10555-017-9715-8","article-title":"Non-coding RNAs, epigenetics, and cancer: tying it all together","volume":"37","author":"Ferreira","year":"2018","journal-title":"Cancer Metastas-. Rev."},{"key":"10.1016\/j.critrevonc.2025.104719_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154090","article-title":"Curcumae rhizoma and its major constituents against hepatobiliary disease: pharmacotherapeutic properties and potential clinical applications","volume":"102","author":"Gao","year":"2022","journal-title":"Phytomedicine"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104719_bib15","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/febs.14786","article-title":"Mitochondrial metabolism is inhibited by the HIF1\u03b1-MYC-PGC-1\u03b2 axis in BRAF V600E thyroid cancer","volume":"286","author":"Gao","year":"2019","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104719_bib16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1089\/thy.2011.0387","article-title":"Iodine-deficiency-induced long lasting angiogenic reaction in thyroid cancers occurs via a vascular endothelial growth factor-hypoxia inducible factor-1-dependent, but not a reactive oxygen species-dependent, pathway","volume":"22","author":"G\u00e9rard","year":"2012","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104719_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/nu11102376","article-title":"Curcumin and cancer","volume":"11","author":"Giordano","year":"2019","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12672-024-00929-x","article-title":"Role of long non-coding RNA ELFN1-AS1 in carcinogenesis","volume":"15","author":"HajiEsmailpoor","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104719_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117163","article-title":"Graveoline attenuates D-GalN\/LPS-induced acute liver injury via inhibition of JAK1\/STAT3 signaling pathway","volume":"177","author":"He","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104719_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030499","article-title":"Tumor hypoxia as a barrier in cancer therapy: why levels matter","volume":"13","author":"Hompland","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104719_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/thy.2018.0509","article-title":"Poorly differentiated carcinoma of the thyroid gland: current status and future prospects","volume":"29","author":"Ibrahimpasic","year":"2019","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104719_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00428-013-1453-x","article-title":"In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior","volume":"463","author":"Ilie","year":"2013","journal-title":"Virchows Arch."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066189","article-title":"Sphingosine-1-phosphate as a regulator of hypoxia-induced factor-1\u03b1 in thyroid follicular carcinoma cells","volume":"8","author":"Kalhori","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13046-023-02724-y","article-title":"Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance","volume":"42","author":"Kao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104719_bib26","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1007\/s11033-020-05669-z","article-title":"Artemisinin and its derivatives: a promising cancer therapy","volume":"47","author":"Kiani","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104719_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ph13090208","article-title":"Hif-1\u03b1 inhibitors could successfully inhibit the progression of differentiated thyroid cancer in vitro","volume":"13","author":"Kim","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104719_bib28","first-page":"1284","article-title":"Epidemiology of thyroid cancer. cancer epidemiol biomarkers prev a publ am assoc cancer res cosponsored by","volume":"31","author":"Kitahara","year":"2022","journal-title":"Am. Soc. Prev. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104719_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12253-017-0232-4","article-title":"Expression of hypoxia-associated protein HIF-1\u03b1 in follicular thyroid cancer is associated with distant metastasis","volume":"24","author":"Klaus","year":"2018","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00428-013-1484-3","article-title":"Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis","volume":"463","author":"Koperek","year":"2013","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/path.2926","article-title":"Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene","volume":"225","author":"Koperek","year":"2011","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/ijo.2013.1913","article-title":"Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells","volume":"43","author":"Lan","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104719_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22168","article-title":"Hypoxia expedites the progression of papillary thyroid carcinoma by promoting the CPT1A-mediated fatty acid oxidative pathway","volume":"85","author":"Liang","year":"2024","journal-title":"Drug Dev. Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/1440-1681.13286","article-title":"Down-regulation of FOXR2 inhibits hypoxia-driven ROS-induced migration and invasion of thyroid cancer cells via regulation of the hedgehog pathway","volume":"47","author":"Liao","year":"2020","journal-title":"Clin. Exp. Pharm. Physiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13277-015-3816-1","article-title":"2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma","volume":"37","author":"Lin","year":"2016","journal-title":"Tumour Biol. J. Int. Soc. Oncodev. Biol. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104719_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/kjm2.12331","article-title":"CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR-18a-5p\/FIH1 axis","volume":"37","author":"Liu","year":"2021","journal-title":"Kaohsiung J. Med Sci."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104719_bib37","doi-asserted-by":"crossref","first-page":"28650","DOI":"10.18632\/oncotarget.15622","article-title":"Expression of HIF-1\u03b1 in medullary thyroid cancer identifies a subgroup with poor prognosis","volume":"8","author":"Lodewijk","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104719_bib38","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa182","article-title":"Lysine-specific demethylase 1 affects the progression of papillary thyroid carcinoma via HIF1\u03b1 and microRNA-146a","volume":"105","author":"Long","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2025.104719_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-024-02388-1","article-title":"HYPOXIA induces lncRNA HOTAIR for recruiting RELA in papillary thyroid cancer cells to upregulate miR-181a and promote angiogenesis","author":"Lu","year":"2024","journal-title":"J. Endocrinol. Invest"},{"key":"10.1016\/j.critrevonc.2025.104719_bib40","article-title":"Cause and consequence of heterogeneity in human mesenchymal stem cells: challenges in clinical application","volume":"260","author":"Lyu","year":"2024","journal-title":"Pathol. Res Pr."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104719_bib41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00268-017-4331-x","article-title":"Hypoxia increases thyroid cancer stem cell-enriched side population","volume":"42","author":"Mahkamova","year":"2018","journal-title":"World J. Surg."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104719_bib42","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1248\/cpb.49.1368","article-title":"Medicinal foodstuffs. XXVII. Saponin constituents of gotu kola (2): structures of new ursane- and oleanane-type triterpene oligoglycosides, centellasaponins B, C, and D, from Centella asiatica cultivated in Sri Lanka","volume":"49","author":"Matsuda","year":"2001","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104719_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jcmm.13465","article-title":"Emerging role of Twist1 in fibrotic diseases","volume":"22","author":"Ning","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104719_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054507","article-title":"miR-210 expression is strongly hypoxia-induced in anaplastic thyroid cancer cell lines and is associated with extracellular vesicles and argonaute-2","volume":"24","author":"Powell","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104719_bib45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fendo.2020.00102","article-title":"Update on fundamental mechanisms of thyroid cancer","volume":"11","author":"Prete","year":"2020","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/pho.2015.3968","article-title":"Low-level laser therapy promoted aggressive proliferation and angiogenesis through decreasing of transforming growth factor-\u03b21 and Increasing of Akt\/hypoxia inducible factor-1\u03b1 in anaplastic thyroid cancer","volume":"34","author":"Rhee","year":"2016","journal-title":"Photo. Laser Surg."},{"key":"10.1016\/j.critrevonc.2025.104719_bib47","doi-asserted-by":"crossref","DOI":"10.25259\/Cytojournal_9_2022","article-title":"The diagnostic value of add-on thyroid cell block in the evaluation of thyroid lesions","volume":"20","author":"Saharti","year":"2023","journal-title":"Cytojournal"},{"key":"10.1016\/j.critrevonc.2025.104719_bib48","doi-asserted-by":"crossref","first-page":"7928200","DOI":"10.1155\/2022\/7928200","article-title":"Advances in understanding the role of aloe emodin and targeted drug delivery systems in cancer","volume":"2022","author":"\u015eeker Karatoprak","year":"2022","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.critrevonc.2025.104719_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib50","first-page":"5191","article-title":"Emodin suppresses angiogenesis and metastasis in anaplastic thyroid cancer by affecting TRAF6\u2011mediated pathways in vivo and in vitro","volume":"18","author":"Shi","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104719_bib52","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","article-title":"Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy","volume":"17","author":"Song","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother. Pharm."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104719_bib55","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/1535370214555665","article-title":"Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells","volume":"240","author":"Tan","year":"2015","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34154-8","article-title":"NADPH oxidase NOX4 is a glycolytic regulator through mROS-HIF1\u03b1 axis in thyroid carcinomas","volume":"8","author":"Tang","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104719_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101872","article-title":"Role of hypoxia and Rac1 inhibition in the metastatic cascade","volume":"16","author":"T\u00e1trai","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104719_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/mc.23648","article-title":"HIF-1\u03b1 regulates the cell viability in radioiodine-resistant papillary thyroid carcinoma cells induced by hypoxia through PKM2\/NF-\u03baB signaling pathway","volume":"63","author":"Wang","year":"2024","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib59","first-page":"322","article-title":"Overexpression of HIF-1\u03b1, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma","volume":"7","author":"Wang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104719_bib60","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/589423","article-title":"Overexpression of HIF-2\u03b1, TWIST, and CXCR4 is associated with lymph node metastasis in papillary thyroid carcinoma","volume":"2013","author":"Wang","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12672-024-01002-3","article-title":"The regulation of hypoxia-related lncRNAs in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Discov. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104719_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284242","article-title":"Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST\/miR-93\/HIF-1a pathway","volume":"18","author":"Yang","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2025.104719_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101809","article-title":"TRPC5 expression promotes the proliferation and invasion of papillary thyroid carcinoma through the HIF-1\u03b1\/Twist pathway","volume":"39","author":"Yang","year":"2024","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib64","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12935-023-03021-6","article-title":"The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1\u03b1\/VEGF signaling pathway","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104719_bib65","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41388-023-02659-w","article-title":"Hypoxia switches TET1 from being tumor-suppressive to oncogenic","volume":"42","author":"Yang","year":"2023","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104719_bib66","doi-asserted-by":"crossref","DOI":"10.3892\/or.2024.8716","article-title":"Effect of hypoxia\u2011HIF\u20111\u03b1\u2011periostin axis in thyroid cancer","volume":"51","author":"Yang","year":"2024","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104719_bib67","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3349\/ymj.2015.56.6.1503","article-title":"Hypoxia induces epithelial-mesenchymal transition in follicular thyroid cancer: involvement of regulation of twist by hypoxia inducible factor-1\u03b1","volume":"56","author":"Yang","year":"2015","journal-title":"Yonsei Med J."},{"key":"10.1016\/j.critrevonc.2025.104719_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12935-019-0730-4","article-title":"SIRT6\/HIF-1\u03b1 axis promotes papillary thyroid cancer progression by inducing epithelial-mesenchymal transition","volume":"19","author":"Yang","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","article-title":"Metabolic reprogramming: the emerging concept and associated therapeutic strategies","volume":"34","author":"Yoshida","year":"2015","journal-title":"J. Exp. Clin. Cancer Res. [Internet]"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113716","article-title":"Hypoxic papillary thyroid carcinoma cells-secreted exosomes deliver miR-221-3p to normoxic tumor cells to elicit a pro-tumoral effect by regulating the ZFAND5","volume":"431","author":"Yu","year":"2023","journal-title":"Exp. Cell Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104719_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081197","article-title":"Targeting oncogenic BRAF: past, present, and future","volume":"11","author":"Zaman","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104719_bib72","first-page":"1052","article-title":"BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer","volume":"23","author":"Zerilli","year":"2010","journal-title":"Mod. Pathol. J. U. S. Can. Acad. Pathol. Inc."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104719_bib73","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.7150\/thno.66142","article-title":"KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt\/\u03b2-catenin signaling pathway","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4274\/balkanmedj.galenos.2023.2023-7-123","article-title":"Asiaticoside down-regulates HIF-1\u03b1 to inhibit proliferation, migration, and angiogenesis in thyroid cancer cells","volume":"41","author":"Zhang","year":"2024","journal-title":"Balk. Med. J."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104719_bib75","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1039\/D4CC06510G","article-title":"Immunoadjuvant-functionalized metal-organic frameworks: synthesis and applications in tumor immune modulation","volume":"61","author":"Zhao","year":"2025","journal-title":"Chem. Commun. (Camb. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104719_bib76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41392-023-01652-9","article-title":"Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104719_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e14714","article-title":"HIF1A overexpression predicts the high lymph node metastasis risk and indicates a poor prognosis in papillary thyroid cancer","volume":"9","author":"Zhao","year":"2023","journal-title":"Heliyon"},{"issue":"60","key":"10.1016\/j.critrevonc.2025.104719_bib78","doi-asserted-by":"crossref","first-page":"101475","DOI":"10.18632\/oncotarget.21135","article-title":"Galectin-3 induced by hypoxia promotes cell migration in thyroid cancer cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104719_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1370800","article-title":"Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment","volume":"15","author":"Zhi","year":"2024","journal-title":"Front Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104719_bib80","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.1021\/acs.jmedchem.3c00337","article-title":"Novel 1,4-dihydropyridines as specific binders and activators of SIRT3 impair cell viability and clonogenicity and downregulate hypoxia-induced targets in cancer cells","volume":"66","author":"Zwergel","year":"2023","journal-title":"J. Med Chem."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:28:41Z","timestamp":1749500921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":80,"alternative-id":["S1040842825001076"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104719","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape of hypoxia in thyroid cancer pathogenesis and treatment","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104719"}}